← WBM framework

Drug derivative coverage

For each drug, the metabolites (derivatives) VMH models in the whole-body reconstruction, compared with the derivatives reported in the Dorrestein ADRC cohort. A VMH derivative is supported when Dorrestein reported a matching mass shift, additional in WBM when it was not, and a Dorrestein modification with no VMH match is missing from WBM (high-confidence modifications only).

Research & education comparison — not clinical or diagnostic. Snapshot 2026-07-14. VMH masses from mol files (reconws_drug_reaction → wbm_smatrix (drug-reaction metabolites), masses from ctf/mets/molFiles).

71
Drugs compared
743
VMH derivatives
90
12%
Supported by Dorrestein
653
Additional in WBM
21
Missing from WBM

VMH-modelled vs Dorrestein-reported derivatives

VMH derivativesmodelled — 743Dorresteinreported — 111653additional in WBM(not reported)90supported21missing from WBM

VMH models 743 derivatives across 71 drugs; the 111 high-confidence derivatives Dorrestein reported overlap in 90 (12% of VMH), leaving 653 modelled but not reported and only 21 reported-but-missing.

Does Dorrestein support the WBM's biofluid assignment?

Plasma → blood [bc], fecal → feces [fe]. Where the WBM routes a drug to a biofluid, Dorrestein largely confirms it; where Dorrestein reports a compound the WBM doesn't route there, it's a candidate routing gap.

98/162
parents [bc] confirmed in plasma
141/159
parents [fe] confirmed in feces
3
parent routing gaps
66
derivative routing gaps
Verified parent gaps — Dorrestein detected in a biofluid the WBM doesn't route to:
  • norverapamil— Dorrestein: plasma + feces; WBM: in no biofluid (nverp)add [bc] + [fe]
  • prednisolone— Dorrestein: plasma; WBM: in no biofluid (prdnsl)add [bc]
  • quetiapine sulfoxide— Dorrestein: feces; WBM: [bc]/portal/[u], not [fe] (quetsulfo)add [fe]

At the derivative level, 54 metabolites Dorrestein reported in feces are not routed to [fe] in the WBM (and 12 plasma → [bc]) — mostly hydroxyl/oxidation metabolites modelled but not transported to a biofluid. Candidates for review, not confirmed structures.

Click a drug to list its derivatives below.

Select a drug to list its VMH derivatives, which are supported by Dorrestein, and which are missing.

A VMH derivative is "supported" if Dorrestein detected a mass shift matching it; "additional in WBM" if not. "Missing from WBM" = a high-confidence Dorrestein modification (hydroxyl, di-hydroxyl, glucuronide, sulfate, acetyl, oxo, demethyl) with no matching VMH derivative.

Feedback